End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings

Authors

Ann T. Farrell, US Food and Drug Administration
Shalini Shenoy, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2019

Volume

3

Issue

23

First Page

4002

Last Page

4020

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019000883

Rights and Permissions

Ann T. Farrell, Julie Panepinto, Ankit A. Desai, Adetola A. Kassim, Jeffrey Lebensburger, Mark C. Walters, Daniel E. Bauer, Rae M. Blaylark, Donna M. DiMichele, Mark T. Gladwin, Nancy S. Green, Kathryn Hassell, Gregory J. Kato, Elizabeth S. Klings, Donald B. Kohn, Lakshmanan Krishnamurti, Jane Little, Julie Makani, Punam Malik, Patrick T. McGann, Caterina Minniti, Claudia R. Morris, Isaac Odame, Patricia Ann Oneal, Rosanna Setse, Poornima Sharma, Shalini Shenoy; End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Adv 2019; 3 (23): 4002–4020. doi: https://doi.org/10.1182/bloodadvances.2019000883

Recommended Citation

Farrell, Ann T.; Shenoy, Shalini; and al., et, "End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings." Blood Advances. 3, 23. 4002 - 4020. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8573